## Edgar Filing: Arbuckle Stuart A - Form 4

Arbuckle Sti Form 4	uart A										
February 05, 2018 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction Form 5 See Instruction Section 17(a) of the Public Utility Holding Company Act of 1935 or Sect 30(h) of the Investment Company Act of 1940						ERSHIP OF Act of 1934, 1935 or Section	OMB Number: Expires: Estimated a burden hour response	•			
1(b). (Print or Type ]	Responses)										
1. Name and Address of Reporting Person <u>*</u> Arbuckle Stuart A			2. Issuer Name <b>and</b> Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) EX CEUTICALS RATED, 50 NOI	(Middle) RTHERN		Earliest Tr ay/Year)	-			Director X Officer (give below) EVP\Chief		Owner er (specify officer	
Filed(Mon				ndment, Date Original tth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
BOSTON, I		(7:0)						Person			
(City) 1.Title of Security (Instr. 3)	(State) 2. Transaction Da (Month/Day/Year		ned 1 Date, if	3. Transactic Code (Instr. 8)	4. Securi or(A) or Di (Instr. 3,	ties Adisposed 4 and (A) or	cquired d of (D)	ired, Disposed of, 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	or Beneficiall 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Common Stock	02/02/2018			М	2,156	A	\$ 91.05	44,108	D		
Common Stock	02/02/2018			<b>S</b> <u>(1)</u>	2,156	D	\$ 169.42	41,952	D		
Common Stock								140	I	401(k)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: Arbuckle Stuart A - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. H Der Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 91.05	02/02/2018		М	2,156	(2)	02/01/2026	Common Stock	2,156	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210			EVP\Chief Commercial Officer			
Signatures						

### /s/ Omar White, Attorney-in-Fact

02/05/2018

# \*\*Signature of Reporting Person Date Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
- (2) The option vests in 16 quarterly installments from 2/2/2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.